Vardiman James W, Harris Nancy Lee, Brunning Richard D
Department of Pathology, University of Chicago, IL 60637, USA.
Blood. 2002 Oct 1;100(7):2292-302. doi: 10.1182/blood-2002-04-1199.
A World Health Organization (WHO) classification of hematopoietic and lymphoid neoplasms has recently been published. This classification was developed through the collaborative efforts of the Society for Hematopathology, the European Association of Hematopathologists, and more than 100 clinical hematologists and scientists who are internationally recognized for their expertise in hematopoietic neoplasms. For the lymphoid neoplasms, this classification provides a refinement of the entities described in the Revised European-American Lymphoma (REAL) Classification-a system that is now used worldwide. To date, however, there has been no published explanation or rationale given for the WHO classification of the myeloid neoplasms. The purpose of this communication is to outline briefly the WHO classification of malignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences.
世界卫生组织（WHO）最近发布了造血与淋巴组织肿瘤分类。该分类是通过血液病理学协会、欧洲血液病理学家协会以及100多位临床血液学家和科学家的共同努力制定而成，这些专家在造血肿瘤领域的专业知识在国际上得到认可。对于淋巴组织肿瘤，该分类对《欧美淋巴瘤修订版（REAL）分类》中描述的实体进行了细化——该系统目前在全球范围内使用。然而，迄今为止，尚未有关于WHO髓系肿瘤分类的解释或基本原理的发布。本交流的目的是简要概述WHO恶性髓系疾病分类，提请注意它与先前分类方案之间的主要差异，并提供这些差异的基本原理。
